XDH and chronic kidney disease: Although, at present, UA may be one of the ignored risk factors for CKD and the clinical use of UA-lowering drugs which include allopurinol and febuxostat is largely confined to gout management, discovering the potential value of XO inhibitors for preventing kidney fibrosis and CKD progression will provide additional valuable tools for managing CKD.